檢索結果 - D. Ross Camidge

Refine Results
  1. 1
    The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

    The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers 由 Adam Atherly, D. Ross Camidge

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Treating ALK-positive lung cancer—early successes and future challenges

    Treating ALK-positive lung cancer—early successes and future challenges 由 D. Ross Camidge, Robert C. Doebele

    出版 2012
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    The epidemiology of self‐poisoning in the UK

    The epidemiology of self‐poisoning in the UK 由 D. Ross Camidge, Rachael Wood, D. Nicholas Bateman

    出版 2003
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

    ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer 由 Benjamin Solomon, Marileila Varella‐Garcia, D. Ross Camidge

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    The Insulin-Like Growth Factor Pathway in Lung Cancer

    The Insulin-Like Growth Factor Pathway in Lung Cancer 由 Rafał Dziadziuszko, D. Ross Camidge, Fred R. Hirsch

    出版 2008
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment

    Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment 由 Sinéad Noonan, Peter B. Sachs, D. Ross Camidge

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case Report

    L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case Report 由 Urs Weber, Kurtis D. Davies, D. Ross Camidge

    出版 2024
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    The impact of socioeconomic status on access to cancer clinical trials

    The impact of socioeconomic status on access to cancer clinical trials 由 Katherine Sharrocks, James Spicer, D. Ross Camidge, Sophie Papa

    出版 2014
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  9. 9
    Update to Rociletinib Data with the RECIST Confirmed Response Rate

    Update to Rociletinib Data with the RECIST Confirmed Response Rate 由 Lecia V. Sequist, Jean‐Charles Soria, D. Ross Camidge

    出版 2016
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  10. 10
    Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

    Targeting MET in Lung Cancer: Will Expectations Finally Be MET? 由 Alexander Drilon, Federico Cappuzzo, Sai‐Hong Ignatius Ou, D. Ross Camidge

    出版 2016
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  11. 11
    Mobocertinib: Mechanism of action, clinical, and translational science

    Mobocertinib: Mechanism of action, clinical, and translational science 由 Michael J. Hanley, D. Ross Camidge, Robert J. Fram, Neeraj Gupta

    出版 2024
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer

    Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer 由 Scott A. Kono, Lynn E. Heasley, Robert C. Doebele, D. Ross Camidge

    出版 2012
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  13. 13
    A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer

    A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer 由 Jose M. Pacheco, D. Ross Camidge, Robert C. Doebele, Erin L. Schenk

    出版 2019
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  14. 14
    Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy

    Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy 由 Colton Ladbury, Chad G. Rusthoven, D. Ross Camidge, Brian D. Kavanagh, Sameer K. Nath

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

    On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics 由 Lina Y. Dimberg, Charles Anderson, D. Ross Camidge, Kian Behbakht, Andrew Thorburn, Heide L. Ford

    出版 2012
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  16. 16
    A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry

    A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Tr... 由 Caroline E. McCoach, Eamon M. Berge, Xian Lu, Anna E. Barón, D. Ross Camidge

    出版 2015
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  17. 17
    Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer

    Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell... 由 Emily R. York, Marileila Varella‐Garcia, Tami J. Bang, Dara L. Aisner, D. Ross Camidge

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer

    Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer 由 Andrew Weickhardt, Dara L. Aisner, Wilbur A. Franklin, Marileila Varella‐Garcia, Robert C. Doebele, D. Ross Camidge

    出版 2012
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  19. 19
    Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib

    Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib 由 Evelyn M. Brosnan, Andrew Weickhardt, Xian Lu, Delee A. Maxon, Anna E. Barón, Michel Chonchol, D. Ross Camidge

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer

    DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer 由 Kurtis D. Davies, Aprille Lomboy, Carolyn A. Lawrence, Michael Yourshaw, Gregary T. Bocsi, D. Ross Camidge, Dara L. Aisner

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: